Want to see DE:DMP full AI Analyst Report?
DMP Stock Chart & Stats
€40.30
€0.45(1.12%)
At close: 4:00 PM EDT
€40.30
€0.45(1.12%)
Day’s Range― - ―
52-Week Range€31.70 - €51.90
Previous CloseN/A
Volume31.90K
Average Volume (3M)18.50K
Market Cap
€1.97B
Enterprise Value€3.31K
Total Cash (Recent Filing)€254.00M
Total Debt (Recent Filing)€1.04B
Price to Earnings (P/E)14.8
Beta0.45
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.1%
Share Statistics
EPS (TTM)2.69
Shares Outstanding49,540,810
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.00Price Target Upside9.18% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.59
Revenue Forecast (FY)€1.20B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And ProfitabilityThe strong TTM rebound indicates renewed commercial momentum, while double-digit net and EBIT margins show Dermapharm converts sales into meaningful profit. Sustaining this performance would strengthen earnings capacity over the medium term.
Healthy Free Cash Flow GenerationRobust and growing free cash flow provides internal funding for investment, debt service and shareholder returns. Conversion of about 82% of net income into free cash supports the quality and resilience of reported earnings.
Diversified Pharmaceutical Business ModelA portfolio spanning branded medicines, OTC healthcare products and CDMO services diversifies revenue sources. Dermatology and allergy specialization can support focused commercial expertise, while manufacturing services add a more contracted revenue stream.
Bears Say
Elevated LeverageDespite improvement, leverage remains a material balance-sheet risk. Meaningful reliance on debt can constrain financial flexibility, increase sensitivity to financing costs and reduce the funds available for growth or unexpected operating needs.
Volatile Margin ProfileRecent profitability is healthy, but the historical volatility suggests current earnings margins may not represent a stable long-term baseline. Fluctuating margins can make forecasting harder and weaken confidence in sustainable earnings power.
Mixed Cash ConversionFree cash flow remains strong, but operating cash flow below net income points to working-capital or timing headwinds. Persistent weak conversion could increase funding needs and make cash generation more variable than accounting profits.
DMP FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
Dermapharm Holding SE lowest stock price was €31.70 and its highest was €51.90 in the past 12 months.
What is Dermapharm Holding SE’s market cap?
Dermapharm Holding SE’s market cap is €1.97B.
When is Dermapharm Holding SE’s upcoming earnings report date?
Dermapharm Holding SE’s upcoming earnings report date is Nov 12, 2026 which is in 78 days.
How were Dermapharm Holding SE’s earnings last quarter?
Dermapharm Holding SE released its earnings results on Aug 25, 2026. The company reported €0.47 earnings per share for the quarter, the consensus estimate of €0.47 by €0.
Is Dermapharm Holding SE overvalued?
According to Wall Street analysts Dermapharm Holding SE’s price is currently Undervalued.
Does Dermapharm Holding SE pay dividends?
Dermapharm Holding SE pays a Annually dividend of €0.88 which represents an annual dividend yield of 2.1%. See more information on Dermapharm Holding SE dividends here
What is Dermapharm Holding SE’s EPS estimate?
Dermapharm Holding SE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermapharm Holding SE have?
Dermapharm Holding SE has 49,540,810 shares outstanding.
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Dermapharm Holding SE reported an EPS of €0.47 in its last earnings report, expectations of €0.47. Following the earnings report the stock price went up 5.528%.
Which hedge fund is a major shareholder of Dermapharm Holding SE?
Currently, no hedge funds are holding shares in DE:DMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dermapharm Holding SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€44.00 (9.18% Upside)
€44.00 (9.18% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
2.10%
Trailing 12-Months
Asset Growth
7.62%
Trailing 12-Months
Company Description
Dermapharm Holding SE
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
DMP Stock 12 Month Forecast
Average Price Target
€44.00
▲(9.18% Upside)







